Clinical Characteristics and Outcomes in HBV Carriers with COVID-19 in WuHan, China: a Retrospective Cohort Study

Jingjing Lu,Mu Hu,Xia Zhou,Hui Zhu,Feilong Wang,Jianhao Huang,Zhongliang Guo,Qiang Li,Qi Yin,Zhifeng Yang

DOI: https://doi.org/10.21203/rs.3.rs-42476/v1

2020-01-01

Abstract:Abstract Background: Coronavirus 2019 (COVID-19) is a novel infectious disease that was first reported in Wuhan, China, but has spread to all parts of the world. At the same time, because China has millions of HBV carriers, HBV infection has become a major public health problem in China. In this study, we aim to describe the clinical features of HBV carriers (AsC) infected with COVID-19 and to assess the factors that may affect the outcome during disease progression.Methods: This retrospective cohort study included 72 patients diagnosed with COVID-19 in Wuhan Jinyintan Hospital. These patients were also diagnosed as HBV carriers. The epidemiological characteristics, demographic features, clinical manifestations, laboratory test, treatment, management and final outcome were collected and analyzed.Results: The median age of 72 patients is 58.5 years old, of which 55.56% (n=40) are male. 20 (30.56%) patients were severe cases and 50 (69.44%) were non-severe cases. Fever is the most common symptom, followed by cough, chest tightness and sputum. Laboratory test results including hematologic, biochemical, infection and coagulation parameters and several indicators, such as Aspartate Aminotransferase (AST), Total Bilirubin (TBil), Direct Bilirubin (DBil), Indirect Bilirubin (IBil), γ-glutamyl Transferase (GGT) showed difference between their admission and discharge. The level of Prealbumin (PA) and Serum Amyloid A (SAA) in the study showed a significant trend from high to low, which has statistical significance.Conclusions: The clinical features of HBV carriers with COVID-19 have obvious systemic symptoms, such as fever, cough, and chest tightness. Compared with liver function data on admission and discharge, SARS-CoV-2 does not directly activate the Hepatitis B virus, and the risk of liver cell damage of HBV carriers with COVID-19 does not increase. Both PA and SAA are sensitive indicators and can be used to evaluate the prognosis and outcome of these patients.